Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.

Mauricio Moel, Girish Harinath, Virginia Lee, Andy Nyquist, Stefanie L Morgan, Anar Isman, Sajad Zalzala

April 2025 Aging (Albany NY)

Synopsis of Social media discussions

This collection of discussions highlights a generally positive and interested outlook on the PEARL trial results, with mentions of the safety profile, benefits for women such as increased lean mass, and the broader implications for aging research. Words like 'gained,' 'benefits,' and 'relatively safe' reflect optimistic tone and focus on health implications, whereas references to specific data and notable authors demonstrate a moderate level of deep engagement.

A
Agreement
 Moderate agreement

Most discussions appear to support the findings, emphasizing the safety and potential benefits of rapamycin.

I
Interest
 High level of interest

The discussions show high curiosity and focus on healthspan improvement, particularly in relation to the trial results.

E
Engagement
 Moderate level of engagement

Participants reference specific outcomes like lean mass gain and safety, indicating moderate engagement.

I
Impact
 Moderate level of impact

The emphasis on novel research and potential health benefits suggests moderate influence on ongoing science and health practices.

Social Mentions

YouTube

2 Videos

Bluesky

12 Posts

Facebook

8 Posts

Twitter

45 Posts

Instagram

6 Posts

Blogs

2 Articles

News

1 Articles

Metrics

Video Views

342

Total Likes

131

Extended Reach

1,052,257

Social Features

76

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Rapamycin's Safety and Benefits for Aging and Longevity

Rapamycin's Safety and Benefits for Aging and Longevity

This 48-week trial evaluated the safety of low-dose rapamycin in healthy adults, showing it's generally safe with potential healthspan benefits, including improved lean tissue and emotional wellbeing in some cases.

Aging-US

September 26, 2025

180 views

Rapamycin's Impact on Safety and Healthspan in a 48-Week Trial

Rapamycin's Impact on Safety and Healthspan in a 48-Week Trial

A 48-week trial evaluated the safety and health effects of low-dose rapamycin in healthy adults. Results indicate it is generally safe, with improvements in emotional wellbeing and lean tissue mass in women, suggesting potential benefits for healthspan.

Aging-US

May 7, 2025

162 views

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    December 5, 2025

    1

  • Aging-US
    @aging-us.bsky.social (Bluesky)


    view full post

    December 5, 2025

  • Carlos Ruiz
    @crGenomics (Twitter)

    RT @AgingJrnl:
    view full post

    November 27, 2025

    1

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    November 26, 2025

    2

    1

  • Aging-US
    @aging-us.bsky.social (Bluesky)


    view full post

    November 26, 2025

  • Javier Gómez
    @javiHistBuff (Twitter)

    RT @AgingJrnl:
    view full post

    November 7, 2025

    2

  • Aging-US
    @AgingJrnl (Twitter)

    #AgingShort:
    view full post

    November 7, 2025

    1

  • Reena Singh
    @EndoReena (Twitter)

    RT @AgingJrnl:
    view full post

    November 7, 2025

    2

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    November 7, 2025

    2

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    November 4, 2025

    2

  • Aging-US
    @aging-us.bsky.social (Bluesky)


    view full post

    November 4, 2025

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    November 1, 2025

    3

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    October 6, 2025

    2

  • Phil
    @EmenoguPhillip1 (Twitter)

    RT @AgingJrnl:
    view full post

    October 2, 2025

    1

  • Phil
    @EmenoguPhillip1 (Twitter)

    https://t.co/um4lrb7Vrw @Potus
    view full post

    October 2, 2025

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    September 26, 2025

    4

    1

  • Aging-US
    @aging-us.bsky.social (Bluesky)


    view full post

    September 26, 2025

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    September 17, 2025

    4

  • Aging-US
    @aging-us.bsky.social (Bluesky)


    view full post

    September 17, 2025

  • Aging-US
    @AgingJrnl (Twitter)

    #AgingShort:
    view full post

    September 12, 2025

    1

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    September 12, 2025

    2

  • Aging-US
    @aging-us.bsky.social (Bluesky)

    #BehindtheStudy: Dr. Stefanie Morgan joins Dr. Robert Dudley from AgelessRx to discuss a #research paper she co-authored in Volume 17, Issue 4, titled “Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.”
    view full post

    September 4, 2025

  • Aging-US
    @AgingJrnl (Twitter)

    #BehindtheStudy: Dr. Stefanie Morgan joins Dr. Robert Dudley @agelessrx_ to discuss a #research paper she co-authored in Volume 17, Issue 4, titled “Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.”
    view full post

    August 6, 2025

    3

  • Madam Mitochondria
    @Madam_Mito (Twitter)

    @ParrishLiz https://t.co/VqHkZ08biL
    view full post

    July 18, 2025

    2

  • Aging-US
    @AgingJrnl (Twitter)

    #BehindtheStudy: Dr. Stefanie Morgan joins Dr. Robert Dudley @agelessrx_ to discuss a #research paper she co-authored in Volume 17, Issue 4, titled “Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.”
    view full post

    July 7, 2025

    3

  • Farah Darwish
    @farah_lovescats (Twitter)

    RT @AgingJrnl:
    view full post

    July 7, 2025

    2

  • Aging-US
    @AgingJrnl (Twitter)

    #AgingShort:
    view full post

    July 7, 2025

    2

  • QuantumAI+Crispr3D=QuInCy=QAI&C3D=LA
    @1LEOOEL1 (Twitter)

    RT @AgingJrnl:
    view full post

    July 7, 2025

    2

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    July 7, 2025

    6

    2

  • Aging-US
    @AgingJrnl (Twitter)

    #BehindtheStudy: Dr. Stefanie Morgan joins Dr. Robert Dudley @agelessrx_ to discuss a #research paper she co-authored in Volume 17, Issue 4, titled “Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.”
    view full post

    June 6, 2025

    3

  • Aging-US
    @aging-us.bsky.social (Bluesky)

    Dr. Stefanie Morgan joins Dr. Robert Dudley from AgelessRx to discuss a #research paper she co-authored in Volume 17, Issue 4 of Aging (Aging-US) titled “Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.” www.youtube.com/watch?v=2qlI... #aging #rapamycin
    view full post

    June 6, 2025

  • The Longevist
    @Dr_coachbear (Twitter)

    RT @AgingBiology: Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results https://t.co/Oahoo1LRr1
    view full post

    May 18, 2025

    3

  • Lisa Vlad
    @LisaVlad2 (Twitter)

    RT @AgingBiology: Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results https://t.co/Oahoo1LRr1
    view full post

    May 18, 2025

    3

  • Agingdoc
    @agingdoc1 (Twitter)

    RT @agingdoc1: Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results Mauricio Moel @AbolishAging, @S…
    view full post

    May 18, 2025

    2

  • Aging Science News
    @AgingBiology (Twitter)

    Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results https://t.co/Oahoo1LRr1
    view full post

    May 17, 2025

    25

    3

  • Aging Science News
    @agingbiology.bsky.social (Bluesky)

    Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results www.aging-us.com/article/2062...
    view full post

    May 17, 2025

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    May 7, 2025

    3

  • Aging-US
    @AgingJrnl (Twitter)

    #AgingShort:
    view full post

    May 7, 2025

    3

  • Aging-US
    @aging-us.bsky.social (Bluesky)


    view full post

    May 7, 2025

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    May 7, 2025

    3

  • Hannah Scott
    @covidhannah (Twitter)

    RT @AgingJrnl:
    view full post

    May 7, 2025

    1

  • Aging-US
    @AgingJrnl (Twitter)


    view full post

    May 7, 2025

    2

    1

  • Mind Your Science!
    @MindYourSci (Twitter)

    RT @agingdoc1: Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results https://t.co/nRM1oQ2aeq
    view full post

    May 7, 2025

    1

  • Aging-US
    @aging-us.bsky.social (Bluesky)


    view full post

    May 7, 2025

  • Aging-US
    @aging-us.bsky.social (Bluesky)


    view full post

    May 7, 2025

  • Agingdoc
    @agingdoc1 (Twitter)

    Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results https://t.co/nRM1oQ2aeq
    view full post

    May 7, 2025

    8

    1

  • Aging Papers
    @PapersAging (Twitter)

    Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results https://t.co/oBxyjV3xlQ
    view full post

    May 6, 2025

  • Aging-US
    @aging-us.bsky.social (Bluesky)

    #AgingResearch: "Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results" DOI ⬇️ doi.org/10.18632/agi... #aging #research #openaccess #openscience #peerreview #journal #publishing
    view full post

    May 5, 2025

  • Joshua Parker
    @HealthTechJP (Twitter)

    RT @AgingJrnl: #PaperoftheDay: "Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results" DOI ⬇️ http…
    view full post

    May 5, 2025

    2

  • Fadi Khalil
    @fadi_grace (Twitter)

    RT @AgingJrnl: #PaperoftheDay: "Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results" DOI ⬇️ http…
    view full post

    May 5, 2025

    2

  • Aging-US
    @AgingJrnl (Twitter)

    #PaperoftheDay: "Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results" DOI ⬇️ https://t.co/dllFymyh0q #aging #research #openaccess #openscience #peerreview #journal #publishing
    view full post

    May 5, 2025

    2

    2

  • P.D. Mangan Health & Freedom Maximalist
    @Mangan150 (Twitter)

    Women who took 10 mg rapamycin weekly for a year *gained* lean mass. https://t.co/EjCuNSuSfo
    view full post

    April 16, 2025

    21

    1

  • TimePie (focus on anti-aging science)
    @TimePieChina (Twitter)

    @SajadZMD and the team published the results of PEARL, a one-year human #rapamycin trial crowdfunded by @LifespanIO, finding the benefits were much stronger for women than men. https://t.co/tIXsHNZ9sS https://t.co/T6qVBuisQg
    view full post

    April 15, 2025


  • @Orlando_uy (Twitter)

    Low-dose, intermittent rapamycin administration over 48 weeks is relatively safe in healthy, normative-aging adults, and was associated with significant improvements in lean tissue mass and pain in women. https://t.co/8hjeDrr6sC
    view full post

    April 15, 2025

    1

  • Mind Your Science!
    @MindYourSci (Twitter)

    RT @agingdoc1: Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results Mauricio Moel @AbolishAging, @S…
    view full post

    April 11, 2025

    2

  • Agingdoc
    @agingdoc1 (Twitter)

    Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results Mauricio Moel @AbolishAging, @SZalzalaMD and co-authors | @AgingJrnl https://t.co/nRM1oQ2I3Y
    view full post

    April 9, 2025

    14

    2

  • Naomasa Kawashima
    @NaomasaKawashim (Twitter)

    https://t.co/ZASXiuNIxH
    view full post

    April 7, 2025

  • AgelessRx | Ann Arbor MI - Facebook

    " AgelessRx https://doi.org/10.18632/aging.206235 #aging #trendingwithimpact #rapamycin #geroscience #longevity #healthspan #openaccess #openscience ...
    view full post

    December 15, 2025

    Facebook

  • Unlocking the Secrets of Frailty: A Scientific Perspective on Aging ...

    doi.org/10.18632/aging.206304 #aging #figure #research ... https://doi.org/10.18632/aging.206235 #interview #authorinterview ...
    view full post

    October 2, 2025

    Instagram

  • Longevity & Aging Series (S3, E6): In this #episode, Girish Harinath ...

    https://www.youtube.com/watch?v=7-NvskI8Ve0 Read the #researchpaper at Aging-US.com. https://doi.org/10.18632/aging.206235 #interview ...
    view full post

    September 26, 2025

    Facebook

  • #TrendingWithImpact: Figure 1 from the #researchpaper, “The ...

    https://doi.org/10.18632/aging.206235 #interview #authorinterview #aging #rapamycin #geroscience #longevity #healthspan #openaccess #series. 更 ...
    view full post

    September 17, 2025

    Instagram

  • As canetinhas emagrecedoras PROTEGEM a visão dos pacientes.

    JAMA Network Open Home JAMA Network Open Vol.8,No.8 Vol. 8,No.8 Original Investigation I Ophthalmology GLP-1 Receptor Agonists and ...
    view full post

    September 16, 2025

    Instagram

  • No maior e mais longo ensaio clínico randomizado duplo-cego ...

    69 likes, 3 comments - dr.ricardozimerman on September 15, 2025: " No maior e mais longo ensaio clínico randomizado duplo-cego publicado ...
    view full post

    September 15, 2025

    Instagram

  • AgingShort: Abstract #video about this #research paper #published ...

    ... 10.18632/aging.206235 #aging #trendingwithimpact #rapamycin #geroscience #longevity #healthspan #openaccess #openscience #peerreviewed ...
    view full post

    September 12, 2025

    Facebook

  • Aging-US follows the #guidelines based on the recommendations of ...

    A New Vision for Healthcare: Addressing Aging Before Disease Begins - Aging (Aging-US) Research ... https://doi.org/10.18632/aging.206235 # ...
    view full post

    September 9, 2025

    Facebook

  • A medicina que trata doenças teve sucesso em aumentar e ...

    ... aging”, as pessoas continuaram envelhecendo no mesmo ritmo. A consequência foi a ampliação do “health span gap”. Isto significa que, graças ...
    view full post

    September 7, 2025

    Instagram

  • Low-dose rapamycin shows promise for enhancing healthspan in ...

    Aging. doi.org/10.18632/aging.206235. Currently rated 5.0 by 2 people. Posted in: Drug Trial News | Medical Condition News. Comments (0).
    view full post

    May 7, 2025

    Blogs

  • Low-dose rapamycin improves muscle mass and well-being in ...

    ... 10.18632/aging.206235. Corresponding authors: Stefanie L. Morgan ... 10.18632/aging.206235. Keywords. /Health and medicine/Human health ...
    view full post

    May 7, 2025

    News

  • Results from the PEARL Trial of Rapamycin – Fight Aging!

    Fight Aging! Do you want to live a longer life in good health ... Link: https://doi.org/10.18632/aging.206235. Comments. Would love to ...
    view full post

    April 14, 2025

    Blogs

  • A cloaked human stem-cell-derived neural graft capable of ...

    Aging | doi:10.18632/aging.206235. Mauricio Moel, ... Rakesh Perani ... Extracellular Vesicles in Aging and Age-Related Diseases. How ...
    view full post

    April 10, 2025

    Facebook

  • https://www.mdpi.com/2079-6374/15/4/232 | Facebook

    Extracellular Vesicles in Aging and Age-Related Diseases. How ... Aging | doi:10.18632/aging.206235. Mauricio Moel, ... Roberto Ripa ...
    view full post

    April 9, 2025

    Facebook

  • Aging-US - Aging is #indexed by PubMed/Medline abbreviated as ...

    ... Aging-US.com. https://doi.org/10.18632/aging.206235 #interview #authorinterview #aging #rapamycin #geroscience #longevity #healthspan ...
    view full post

    March 16, 2025

    Facebook

  • Aging's Special Collection on Cell Senescence and Rapamycin ...

    " AgelessRx https://doi.org/10.18632/aging.206235 #aging #trendingwithimpact #rapamycin #geroscience #longevity #healthspan #openaccess ...
    view full post

    February 1, 2025

    Facebook

  • September 15, 2021: Aging (Aging-US) released a new issue of ...

    https://doi.org/10.18632/aging.206235 #interview #authorinterview #aging #rapamycin #geroscience #longevity #healthspan #openaccess #series.
    view full post

    September 15, 2021

    Instagram

Abstract Synopsis

  • A 48-week trial tested the safety and health effects of low-dose rapamycin in healthy adults, finding it generally safe with no increase in adverse events and stable visceral fat levels.
  • Women taking 10 mg rapamycin experienced significant improvements in lean tissue mass and reduced pain, while both dosage groups reported better emotional wellbeing and overall health.
  • The results suggest that intermittent low-dose rapamycin is relatively safe and may provide benefits for healthspan, but further research is needed to explore different doses and long-term effects.